| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-10-01 | Audentes Therapeutics (USA - CA) | vice president | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2014-09-30 | Bayer HealthCare (Germany) OncoMed Pharmaceuticals (USA) | Wnt inhibitor | development manufacturing production |
Cancer Oncology | Milestone | |
| 2014-09-30 | Evotec (Germany) Bayer (Germany) | three clinical candidates | endometriosis | R&D |
Gynecological diseases - Women's health | Milestone |
| 2014-09-30 | Glialogix (USA - CA) National Multiple Sclerosis Society (USA) | GLX1112 | multiple sclerosis | collaboration |
Autoimmune diseases - Neurodegenerative diseases | Collaboration agreement |
| 2014-09-30 | The Lead Discovery Center (LDC) (Germany) Helmholtz Association (Germany) | neuroblastoma and other cancer types | Cancer - Oncology | Collaboration agreement | ||
| 2014-09-30 | Jacobs Engineering Group (USA - CA) Novo Nordisk (Denmark) | R&D facility | construction of new premises services contract |
Construction of new premises | ||
| 2014-09-30 | NovaMedica (Russia) Horus Pharma (France) | ILast®, Macula-Z-Oro, preservative-free Vitamine B12 eye drops | licensing commercialisation |
Ophtalmological diseases | Licensing agreement | |
| 2014-09-29 | Pfizer (USA - NY) Kyowa Hakko Kirin (Japan) | PF-05082566 and mogamulizumab | solid tumors | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2014-09-29 | Baxter (USA - IL) | Establishment of a new subsidiary in the EU | ||||
| 2014-09-29 | Galmed Pharmaceuticals (Israel) Itamar Medical (USA - MA) | EndoPAT™ devices and accessories for endothelial function assessment | services |
Hepatic diseases - Liver diseases - Metabolic diseases | Services contract | |
| 2014-09-29 | Sigmoid Pharma (Ireland) Pendopharm (Canada) | CyCol® | Gastrointestinal diseases - Digestive diseases | Licensing agreement | ||
| 2014-09-29 | Protalix Biotherapeutics (Israel) | Nomination | ||||
| 2014-09-29 | Atox Bio (Israel) Biomedical Advanced Research and Development Authority (BARDA) (USA) | AB103 | necrotizing soft tissue infections (NSTI) and potentially infections caused by biothreats and public health threats that end in sepsis | services |
Infectious diseases | Services contract |
| 2014-09-29 | Kamada (Israel) Baxter (USA - IL) | Glassia® (liquid form of human Alpha-1 Antitrypsin (AAT) administered intravenously) | chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (Alpha1-PI), also known as alpha1- antitrypsin deficiency | collaboration |
Genetic diseases - Respiratory diseases | Collaboration agreement |
| 2014-09-29 | Kymab (UK) | chief operating officer, member of the board of directors | nomination | Cancer - Oncology - Infectious diseases - Inflammatory diseases - Hematological diseases | Nomination | |
| 2014-09-28 | Nicox (France) Nitto Medic (Japan) | AdenoPlus® | acute conjunctivitis | Ophtalmological diseases - Infectious diseases | Distribution agreement | |
| 2014-09-27 | Baxter (USA - IL) Merrimack Pharmaceuticals (USA - MA) | MM-398 (nanoliposomal irinotecan injection) | metastatic pancreatic cancer | Cancer - Oncology | Licensing agreement | |
| 2014-09-26 | Aveo Oncology (USA - MA) BMR-650 E Kendall (USA - CA) Hercules Technology Growth Capital (USA - CA) | termination of a lease agreement loan agreement |
Termination of an agreement | |||
| 2014-09-25 | AP-HP (France) Magnisense (France) | emergency diagnostic tests | cardiovascular diseases | development |
Cardiovascular diseases - Diagnostic | Development agreement |
| 2014-09-25 | Horizon Discovery (UK) undisclosed major global diagnostic development company and US biopharmaceutical company | companion diagnostics for novel, genetically-targeted cancer medicines | services development |
Cancer - Oncology | Services contract |
